FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 179-183

  Zhu, Qingyao ^a   Wang, Tao ^a   Ren, Jinghua ^a   Hu, Kai ^b   Liu, Wei ^c   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Apoptosis; FAS; Metastasis; Nasopharyngeal carcinoma; Polymorphism

Indexed keywords

ADENOSINE; BIOLOGICAL MARKER; FAS ANTIGEN; GUANINE;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER STAGING; CASE CONTROL STUDY; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 72449146698     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.10.024     Document Type: Article

References (35)

1. McDerrmott A.L., Dutt S.N., and Watkinson J.C. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 26 (2001) 82-92
2. Chen D.L., and Huang T.B. A case-control study of risk factors of nasopharyngeal carcinoma. Cancer Lett 117 (1997) 17-22
3. Yu M.C., and Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 421-429
4. Zheng X., Yan L., Nilsson B., Eklund G., and Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 33 (1994) 867-872
5. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
6. Lorenz H.M., Herrmann M., Winkler T., Gaipl U., and Kalden J.R. Role of apoptosis in autoimmunity. Apoptosis 5 (2000) 443-449
7. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
8. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
9. Peters A.M., Kohfink B., Martin H., et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol 27 (1999) 868-874
10. Boldrini L., Faviana P., Gisfredi S., et al. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. Int J Oncol 20 (2002) 155-159
11. Viard-Leveugle I., Veyrenc S., French L.E., Brambilla C., and Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201 (2003) 268-277
12. Keane M.M., Ettenberg S.A., Lowrey G.A., Ruussell E.K., and Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 56 (1996) 4791-4798
13. Müschen M., Warskulat U., and Beckmann M.W. Defining CD95 as a tumor suppressor gene. J Mol Med 78 (2000) 312-325
14. Kanemitsu S., Ihara K., Saifddin A., et al. A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29 (2002) 1183-1188
15. Liakouli V., Manetti M., Pacini A., et al. The - 670G > A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 68 (2009) 584-590
16. Huang Q.R., Danis V., Lassere M., Edmonds J., and Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38 (1999) 645-651
17. Farre L., Bittencourt A.L., Silva-Santos G., et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83 (2008) 220-222
18. Ueda M., Hung Y.C., Terai Y., et al. Fas gene promoter - 670 polymorphism(A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98 (2005) 129-133
19. Sun T., Miao X., Zhang X., Tan W., Xiong P., and Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96 (2004) 1030-1036
20. Zhang Z., Wang L.E., Sturgis E.M., et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12 (2006) 5596-5602
21. Sayama K., Yonehara S., Watanabe Y., and Miki Y. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103 (1994) 330-334
22. Huang Q.R., Morris D., and Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34 (1997) 577-582
23. Shuai K. Interferon-activated signal transduction to the nucleus. Curr Opin Cell Biol 6 (1994) 253-259
24. Xu X., Fu X.Y., Plate J., and Chong A.S. IFN-γ gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 58 (1998) 2832-2837
25. Park J.Y., Lee W.K., Jung D.K., et al. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 15 (2009) 1794-1800
26. Bel Hadi Jrad B., Mahfouth W., Bouaouina N., et al. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233 (2006) 21-27
27. Kang S., Dong S.M., Seo S.S., Kim J.W., and Park S.Y. FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180 (2008) 1-5
28. Liu M.T., Hsieh C.Y., Chang T.H., Lin J.P., Huang C.C., and Wang A.Y. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 33 (2003) 501-508
29. Hofmann G., Langsenlehner U., Langsenlehner T., et al. A common hereditary single nucleotide polymorphism in the gene of FAS and colorectal cancer survival. J Cell Mol Med (2009). http://doi:10.1111/j.1582-4934.2009.00720.x [Electronic publication ahead of print] doi:10.1111/j.1582-4934.2009.00720.x
30. Li C., Larson D., Zhang Z., et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16 (2006) 253-263
31. Zhang H., Sun X.F., Synnerstad I., and Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 13 (2007) 233-237
32. Lai H.C., Sytwu H.K., Sun C.A., et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103 (2003) 221-225
33. Ikehara S.K., Ikehara Y., Matsuo K., et al. A polymorphism of C-to-T substitution at - 31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J Hum Genet 51 (2006) 927-933
34. Yang M., Sun T., Wang L., et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14 (2008) 3230-3236
35. Kripple P., Langsenlehner U., Renner W., Köppel H., and Samonigg H. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96 (2004) 1478-1479